Please assess the completion status of the following clinical trial:

Trial Title: EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent atrial fibrillation (AF), AF persistence for \> 7 days but \< 1 year~* Total AF history \< 2 years~* Written informed consent of the patient~* Age ≥18 years~* Female patients are sterilised or postmenopausal or apply an adequate method for contraception (Pearl index \<1%) and have a negative pregnancy test (ß-HCG) and do not breastfeed/nurse.~Exclusion Criteria:~* Hemodynamic instability or symptoms not allowing cardioversion to be delayed for 3 weeks~* Myocardial infarction within the last 3 months~* Heart failure NYHA class III - IV~* Uncontrolled hypertension, defined as a systolic blood pressure \> 160 mm Hg and/or a diastolic blood pressure \> 95 mm Hg (anti-hypertensive treatment is allowed).~* Pre-treatment with an aldosterone antagonist or other potassium sparing diuretics~* Instable angina pectoris~* Use of Digitalis~* Use of class I or class III antiarrhythmic drugs (must be stopped at least 5 half-life before)~* Contraindication or hypersensitivity to ß-blockers~* Open heart surgery within the last 3 months~* Pregnancy~* Acute and reversible illnesses~* Acute and chronic infection~* Alcohol or drug abuse or a severe progressive extracardiac disease~* Untreated manifest and latent hyper- or hypothyroidism or \< 3 months peripheral euthyroidism (normal fT3)~* Moderate to severe renal insufficiency (Creatinine clearance less than 50 ml/min)~* Patients with liver cirrhosis (Child-Pugh class C)~* Co-administration of strong CYP3A4 inhibitors (e.g. Itraconazole, Ketoconazole, Ritonavir, Nelfinavir, Clarithromycin, Telithromycin and Nephazodon)~* Hypersensitivity against Eplerenone and/or one of the other components of the tablet (see Fachinformation)~* Serum potassium \> 5 mmol/l~* Patients unlikely to comply with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Eplerenone treatment
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).